CF-404 / ContraFect - LARVOL DELTA

CF404. Regional Anesthesia Complications (1 PS, 1 CME) (ASA 2025) - "The forum will discuss risks for infection and ways to prevent, recognize, and treat infectious complications of regional techniques. SessionLearningObjective1: Identify risks for wrong-sided nerve block and discuss ways of preventing this complication.SessionLearningObjective2: Describe a clinical case of a peripheral nerve block resulting in a peripheral nerve injury, identify risks for development of a PNI, and describe best practice of managing a PNI.SessionLearningObjective3: Recognize risks factors for infections complications of regional anesthesia, identification, and treatment in patients undergoing regional techniques."

Anesthesia • Infectious Disease • Orthopedics

CF404. Percutaneous Approaches to Implantation and Repair of Aortic, Mitral, and Tricuspid Valves (ASA 2024) - "Learning Objective 2 Examine approaches to percutaneous repair of the mitral valve.. Learning Objective 3 Compare various techniques and pitfalls for management of anesthesia for percutaneous approaches to the aortic and mitral valve"

Anesthesia • Cardiovascular

CF404. Patients on Mechanical Circulatory Support Presenting for Non-Cardiac Surgery (ASA 2022) - "Discuss and prepare for patients arriving to the operating room on MCS and alter the anesthetic plan accordingly. Focus on the unique challenges patients on MCS present and recognize common complications."

Clinical • Anesthesia • Cardiovascular

Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Anti-Viral Activities and Enables Broad Coverage Combination Therapies. (PubMed, J Virol) - "A 3 mg/kg dose of the novel triple antibody combination CF-404 (i.e. 1 mg/kg of each component bnAb) delivered to the airway was shown to effectively prevent weight-loss and death in mice challenged with ten LD inoculums of either H1N1, H3N2, B/Victoria-lineage, or B/Yamagata-lineage influenza viruses.IMPORTANCE Influenza causes widespread illness in humans and can result in morbidity and death, especially in the very young and elderly populations...The significance of our research is the demonstration that effective therapeutic treatments of multiple relevant influenza types (H1N1, H3N2, and B) can be achieved by airway administration of a single combination of relatively small amounts of three anti-influenza antibodies. This advance exploits the discovery that airway delivery is a more potent way of administering anti-influenza antibodies compared to systemic delivery, making this a feasible and cost-effective therapeutic approach."

Combination therapy • Journal • Infectious Disease